Brought to you by 
Nichi-Iko Pharmaceutical Co., Ltd.
http://www.nichiiko.co.jp/english
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nichi-Iko Pharmaceutical Co., Ltd.
Coronavirus Update: How Should Remdesivir Be Priced? ICER Are In Two Minds
Independent drug cost watchdog updates its twin pricing estimates for Gilead's drug - but dexamethasone could tip the balance again.
Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
Coronavirus Update: Imperial And Morningside Form Social Enterprise For COVID-19 Vaccine
London university ready to launch clinical trials of vaccine based on self-amplifying RNA technology shortly.
Coronavirus Update: More Drugs Enter Trials, UK To Host Latest Vaccine Summit
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Elmed Eisai Co., Ltd
- Nichi-Iko Medical Practice Institution Co., Ltd.
- Yakuhan Pharmaceutical Co., Ltd.
- Nichi-Iko Pharma Tech Co., Ltd.
- Omega Laboratories Limited
- Sagent Pharmaceuticals Inc.
- Nihon Iyakuhin Kogyo Co., Ltd.